Virtual 2021 BioHealth Capital Region Forum

Top 3 by 2023

September 13-14, 2021 Two Half-Days


20% of the top influencers worldwide in vaccine development


World-class tech + big data + biotech + White House Precision Medicine Initiative = new frontiers in patient-centered medicine


MD | DC | VA

Our Goal: To become a Top 3 BioHealth Hub by 2023.

We are the research engine for the nation and the world. A lifeblood of support for taking new medicines to market. A place where health policymakers and patient advocates seek a better way forward. A home to the established and the startup, pioneering big ideas for human health and hope.

Driving Innovation and Entrepreneurship

  • World–renowned research institutions and universities
  • Influential policymakers and advocacy groups pioneering new health strategies
  • World–leading infectious disease research and vaccine development
  • Fastest growing region for healthcare companies in the U.S.
  • Rated #1 in the nation for science and engineering talent
  • Mission control for the National Cancer Moonshot Initiative

BioHealth Capital Region Partners

Leading Children’s Hospitals and Phlow Corp. form an Unprecedented Coalition to Deliver Essential Medicines to Address Pediatric Drug Shortages

March 18, 2021

RICHMOND, Va., March 18, 2021 – Phlow Corp., a U.S.-based, public benefit corporation committed to a bold mission of providing every American with access to affordable, high-quality essential medicines, today joins…

NeoImmuneTech Announces Closing of Initial Public Offering

March 16, 2021

ROCKVILLE, Md.–(BUSINESS WIRE)–NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the closing of its initial public offering of 3,133,334 shares of common stock, equivalent with 15,666,670…

VLP Therapeutics raises $16M Series A for cancer treatment vaccine R&D

March 15, 2021

GAITHERSBURG, Md., March 15, 2021 /PRNewswire/ — US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on March 15 that it has raised US$16 million in a Series A funding round from MIYAKO Capital Co., Ltd., Sojitz Corporation, Konishiyasu…

Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune’s COVID-19 Vaccine Candidate at its Houston Facility

March 12, 2021

GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the expanded agreement,…

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials

March 11, 2021

– 100% protection against severe disease – Final analysis in U.K. trial confirms 96% efficacy against original strain of COVID-19 – Efficacy against variants confirmed in U.K. and South Africa GAITHERSBURG, Md., March 11, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a…

Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis

March 10, 2021

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to advancing therapies that address the global rise of multi-drug resistant infections, announced today that the U.S. Food and…